Left Ventricular Assist Device is a Viable Therapy in End Stage Hypertrophic Cardiomyopathy

Left Ventricular Assist Device (LVAD) therapy use is increasing rapidly in advanced heart failure (HF). Little data exists on the application of this therapy in patients with advanced HF due to hypertrophic cardiomyopathy (HCM). Altered ventricular geometry, thickened septum and reduced LV end-diastolic diameter (LVEDD) in HCM may lead to increased suction events, arrhythmias and inflow cannula malfunction. We hypothesized that patients with end stage HCM benefit from LVAD therapy and have a similar rate of complications to those with ischemic or dilated CM. Between 2009 and 2014, 5 patients with end stage HCM (HCM and EF <50%), were implanted with either a HeartMate II ® (80%) or HVAD® (20%) device, as a bridge-to-transplant (BTT) (80%) or destination therapy (DT) (20%). We compared baseline characteristics, surgical, and long-term clinical outcomes between these patients and those receiving an LVAD for end stage dilated and ischemic CM (n=214) during that time frame. The HCM cohort had a smaller LVEDD (5.2 versus 6.9 cm, p=0.001) and a higher LVEF (28% v 18%, p=0.002). Citation: Byku A.et al. (2017) “Left Ventricular Assist Device is a Viable Therapy in End Stage Hypertrophic Cardiomyopathy”. The VAD Journal, 3. doi: https://doi.org/10.13023/VAD.2017. 08 Editor-in-Chief: Maya Guglin, University of Kentucky Received: May 25, 2017 Accepted July 4, 2017 Published: July 4, 2017 © 2017 The Author(s). This is an open access article published under the terms of the Creative Commons AttributionNonCommercial 4.0 International License (https://creativecommons.org/licens es/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided that the original author(s) and the publication source are credited. Funding: Not applicable Competing interests: Not applicable